Information Provided By:
Fly News Breaks for February 25, 2019
IRWD
Feb 25, 2019 | 07:04 EDT
H.C. Wainwright analyst Raghuram Selvaraju upgraded Ironwood Pharmaceuticals to Neutral and raised his price target for the shares to $14 from $11.50. The analyst anticipates "moderate growth" in Linzess within the U.S. market going forward, as well as accelerating contributions from ex-U.S. territories, particularly China. Ironwood's performance in the most recent quarter handily beats estimates, he points out.
News For IRWD From the Last 2 Days
There are no results for your query IRWD